Related Experiment Video
Updated: Aug 8, 2026
10:32
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
Published on: August 24, 2015
Safety of plasma derivatives
1Department of Clinical Immunology, University Hospital, Aarhus/Skejby, Denmark.
Haemostasis
|September 1, 1994
Summary
Patient safety in plasma-derived therapy relies on a comprehensive approach, from donor screening and viral inactivation to product quality control and monitoring for complications like alloantibodies. Ensuring plasma derivative safety involves a long chain of interdependent measures.
Area of Science:
- Immunology
- Hematology
- Virology
Background:
- Plasma-derived therapies are crucial for treating various medical conditions, but carry inherent risks.
- Ensuring recipient safety involves rigorous donor screening, viral inactivation, and product quality control.
- Potential complications include viral transmission and the development of alloantibodies.
Purpose of the Study:
- To review the multifaceted aspects of patient safety in plasma-derived substitution therapy.
- To highlight key safety measures throughout the plasma product lifecycle.
- To discuss complications such as alloantibody formation and historical side effects.
Main Methods:
- Review of clinical treatment practices and safety protocols in plasma therapy.
- Analysis of viral inactivation techniques and their efficacy.
- Examination of patient outcomes, including inhibitor development and adverse reactions.
Main Results:
- Safety is a continuous process from donor selection to final product administration.
- Viral inactivation methods are critical but vary in effectiveness.
- The development of inhibitors (alloantibodies) is a significant complication, with recent observations suggesting a link to specific processing methods (e.g., pasteurization vs. dry-heat inactivation).
- Improved purity of concentrates has reduced historical side effects like hemolytic anemia and anaphylactoid reactions.
Conclusions:
- Patient safety in plasma derivative therapy is a complex, multi-step process requiring meticulous attention at each stage.
- Continuous monitoring and research are essential to mitigate risks and improve the safety profile of plasma products.
- Understanding potential neoantigen introduction and alloantibody formation is vital for optimizing patient outcomes.
Related Concept Videos
02:45Blood Transfusion and Agglutination
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...